- Health Canada DPD: APO-BILASTINE TABLETS (APOTEX INC, DIN 02549883) · product monograph (PDF)
- Health Canada DPD: AURO-BILASTINE (AURO PHARMA INC, DIN 02541556) · product monograph (PDF)
- Spain CIMA (Spanish): search for “bilastina” (external search; text not reproduced)
Links only. These regulators' terms do not clearly permit reproducing the documents, so no text is shown here. Check the Philippine package insert in the products table.
Contraindications
- Hypersensitivity
Dosing: Adult
- Allergic rhinoconjunctivitis and urticaria (adults and adolescents 12 years and older): 20 mg once daily, 1 hour before or 2 hours after food or fruit juice
Dosing: Altered kidney function
Bilastine is a non-sedating antihistamine that is not metabolized; about 28% is excreted unchanged in urine. Exposure rises about 2.3-fold in severe kidney impairment, but the European label needs no dose change in adults. It advises avoiding P-glycoprotein inhibitors (such as ketoconazole, erythromycin, cyclosporine, ritonavir, diltiazem) in moderate or severe kidney impairment. It has no US FDA label.
Kidney function measure: SmPC pharmacokinetic groups use glomerular filtration rate (GFR, mL/min/1.73 m2); no dose adjustment at any level. Bands shown on creatinine clearance (CrCl).
Show full dosing details
- CrCl ≥60 mL/min
- Usual: 20 mg once daily, 1 hour before or 2 hours after food or fruit juice (SmPC).
- CrCl 30–59 mL/min
- No dose adjustment (SmPC). Moderate impairment: avoid P-glycoprotein inhibitors (ketoconazole, erythromycin, cyclosporine, ritonavir, diltiazem).
- CrCl 15–29 mL/min
- No dose adjustment (SmPC); AUC about 2.3-fold higher in severe impairment. Avoid P-glycoprotein inhibitors.
- CrCl <15 mL/min (not on dialysis)
- No dose adjustment (SmPC). Avoid P-glycoprotein inhibitors.
- Hemodialysis (intermittent)
- Not studied in dialysis (SmPC silent). No adjustment in severe impairment; avoid P-glycoprotein inhibitors.
- Peritoneal dialysis
- Not studied in dialysis.
- CRRT
- Not studied.
- Dialyzable? Not stated (84% to 90% protein-bound).
- Monitoring QT risk factors (hypokalemia, hypomagnesemia, hypocalcemia, bradycardia, QT-prolonging drugs) (SmPC 4.4).
Children (kidney dosing)
Show full dosing details
- eGFR ≥60
- Normal kidney function: usual pediatric dose (SmPC).
- eGFR 30–59
- Safety and efficacy in children with kidney impairment not established (SmPC).
- eGFR 15–29
- Safety and efficacy in children with kidney impairment not established (SmPC).
- eGFR <15 (not on dialysis)
- Safety and efficacy in children with kidney impairment not established (SmPC).
- Hemodialysis (intermittent)
- Not established in children.
- Peritoneal dialysis
- Not established in children.
- CRRT
- Not established in children.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
Source: HPRA (Ireland) product information (February 2026). This generic has no US FDA label.
Dosing: Pediatric
- Approved ages
- 2 years and older, weighing at least 15 kg (SmPC).
- Usual dose
- 2 to 11 years (15 kg or more): 10 mg once daily (orodispersible tablet or oral solution). 12 years and older: 20 mg once daily.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedDosage forms
Philippines
- Tablet: 20 mg
- Oral solution: 2.5 mg/mL
- Orodispersible tablet: 10 mg
Registered products in the Philippines
18 products registered with the Food and Drug Administration (FDA) Philippines list Bilastine as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
All registered products18
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
BalstimaxBilastine | 20 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | One Technodrug Life Sciences Inc.Importer: Ambica International Corporation | DRP-14872-02 | Jan 26, 2029 | |
BilasminBilastine | 20 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | Vamsler Phils. Inc.Importer: Ambica International Corporation | DRP-14872-08 | Jan 26, 2029 | |
BILASYNBilastine | 20 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | Glorious Dexa Mandaya, Inc.Importer: Ambica International Corporation | DRP-14872-09 | Jan 26, 2029 | |
BilatrisBilastine | 20 mg TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | Rx | Ratnatris Pharmaceuticals Pvt. Ltd.India | AMB HK Enterprises Inc. | DRP-19006 | Oct 19, 2031 | |
BilaxtenBilastine | 10 mg Orodispersible TabletAlu/Alu Blister Pack X 10'S(Box of 10's 20's 30's and 50's) | Rx | A. Menarini Manufacturing Logistics and Services S.r.I.Italy | A. Menarini Philippines | DR-XY47344 | Feb 2, 2031 | |
BilaxtenBilastine | 2.5mg/mL Oral SolutionAmber glass bottle (120mL net content) with polypropylene cap and LDPE liner + 25 mL measuring cup (Box of 1's) | Rx | Berlin-Chemie AGGermany | A. Menarini Philippines, Inc. | DR-XY48085 | Jun 2, 2027 | |
BilaxtenBilastine | 20 mg TabletAlu-Alu blister pack Box of 10's; Alu-Alu blister pack Box of 20's; Alu-Alu blister pack Box of 30's; Alu-Alu blister pack Box of 40's; Alu-Alu blister pack Box of 50's; Alu-Alu blister pack Box of 4's (Physician's sample) | Rx | A. Menarini Manufacturing Logistics And Services S.R.LItaly | Importer: A.MENARINI PHILIPPINES, INC. | DR-XY43523 | Jul 7, 2029 | |
BilfastBilastine | 20 mg TabletAlu/Alu Blister Pack x 10's (Box of 100’s) | Rx | Stallion Laboratories Pvt. Ltd.India | Getz Pharma (Phils.), Inc.Importer: Ambica International Corporation | DRP-14872-05 | Jan 26, 2029 | |
BilphilBilastine | 20 mg TabletAlu/Alu Blister Pack X 10's (Box of 30's) | Rx | Exemed PharmaceuticalsIndia | AMB HK Enterprises, Inc. | DRP-18901 | Sep 29, 2031 | |
Bilwin 20Bilastine | 20 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-14872 | Jan 26, 2029 | |
BlastnicBilastine | 20 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | Maed Pharma CorporationImporter: Ambica International Corporation | DRP-14872-03 | Jan 26, 2029 | |
BlazenBilastine | 20 mg TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | Rx | Stallion Laboratories Pvt. Ltd.India | Ajanta Pharma Philippines Inc.Importer: Ambica International Corporation | DRP-14872-01 | Jan 26, 2029 | |
BreezalinBilastine | 20 mg TabletAlu/Alu Blister Pack x 10's (Box of 30's) | Rx | Stallion Laboratories Pvt. Ltd.India | TGP Pharma Inc.Importer: Ambica International Corporation | DRP-14872-04 | Jan 26, 2029 | |
BrilixBilastine | 20 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | Pro Medica Inc.Importer: Ambica International Corporation | DRP-14872-07 | Jan 26, 2029 | |
BylastBilastine | 20 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | The Cathay Drug Co., Inc.Importer: Ambica International Corporation | DRP-14872-10 | Jan 26, 2029 | |
LaxitinBilastine | 20 mg TabletAlu/Alu Blister Pack x 10’s (Box of 50’s) | Rx | Vivimed Labs Ltd.India | Hexagon Pharmaceuticals | DRP-18633 | Aug 11, 2031 | |
NadrizarBilastine | 20 mg TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | Rx | Magbro Healthcare Pvt. Ltd.India | Pharmakon Biotec Inc. | DRP-18767 | Sep 3, 2031 | |
NoneBilastine | 20 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | Rx | Stallion Laboratories Pvt. Ltd.India | South Star DrugImporter: Ambica International Corporation | DRP-14872-06 | Jan 26, 2029 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| P-glycoprotein inhibitors (ketoconazole, erythromycin, cyclosporine, ritonavir, diltiazem) | Avoid | Bilastine AUC up 2-fold, peak up 2- to 3-fold (ketoconazole, erythromycin). | Avoid in moderate or severe kidney impairment; no action needed with normal kidney function. |
| Food, grapefruit and other fruit juices | Minor | Bioavailability falls about 30%. | Take 1 hour before or 2 hours after. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewedAdverse reactions
Common
- Headache (4.0%)
- Somnolence (3.1%)
- Dizziness, fatigue
Serious
- QT prolongation (reported)
Monitoring parameters
- QT risk factors (hypokalemia, hypomagnesemia, hypocalcemia, bradycardia, QT-prolonging drugs) (SmPC 4.4). Kidney
- QT risk factors in susceptible patients
Pharmacokinetics
Key PK parameters
| Bioavailability | 61% |
|---|---|
| Time to peak | About 1.3 hours |
| Half-life | 14.5 hours |
| Half-life in kidney failure (ESKD) kidney | 18.4 hours in severe impairment (GFR <30) vs 9.3 hours normal; AUC 1,708.5 vs 737.4 ng·h/mL |
| Protein binding | 84% to 90% |
| Metabolism (CYP, transporters) | Not significantly metabolized |
| Active metabolites | None |
| Renal excretion kidney | 28.3% unchanged in urine; 66.5% in feces |
| Dialyzability kidney | Not stated |
Formulary and pricing (Philippines)
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Health Products Regulatory Authority (Ireland). Drynol 20 mg tablets SmPC (PA0865/018/001) [HPRA (Ireland) product information, February 2026; no US FDA label]. https://assets.hpra.ie/products/Human/22434/Licence_PA0865-018-001_25022026171031.pdf
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- Menarini International Operations Luxembourg S.A.. (2026). Drynol 20 mg tablets (bilastine) [Summary of product characteristics, licence PA0865/018/001; text revised February 2026]. Health Products Regulatory Authority (Ireland). https://assets.hpra.ie/products/Human/22434/Licence_PA0865-018-001_25022026171031.pdf
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 17, 2026.
Last updated: .